Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Enanta Pharmaceuticals Inc.

KeyBanc analyst Bradley Thomas maintained a Buy rating on Central Garden Pet today and set a price target of $50.00. According to TipRanks, Thomas ...

KeyBanc Keeps Their Buy Rating on Central Garden Pet (CENT)

In a report released today, Brian McNamara from Canaccord Genuity reiterated a Buy rating on Central Garden Pet, with a price target of $50.00. McN...

Market Cap	$216.34M	P/E Ratio	N/A
52W High	$15.34	52W Low	$4.09
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	-11.8%	52W Position	94.6%
Overall Score	49	Value Score	60
Quality Score	23	Technical Score	66

EPS Current Est	$-2.3	EPS Next Est	$-2.26
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ENTA	$14.73	+4.17%	254.94K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ENTA	$14.73	+4.2%	254.94K
3
4
5
6

ENTA

ENTA

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Enanta Pharmaceuticals Inc. Data in Excel

Get Enanta Pharmaceuticals Inc. Data in Excel